Tag: AMX0035

Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study

businessnewstoday- March 10, 2024

Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More

Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS

businessnewstoday- October 1, 2022

RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) from the US Food and Drug Administration (FDA) ... Read More